Pe-22-28 TREK-1 Channel Guide — Mechanism & Applications

A 2019 study published in Nature Neuroscience found that TREK-1 (TWIK-related K+ channel) deletion in mice resulted in heightened mechanical pain sensitivity and altered neuronal excitability patterns. Demonstrating that TREK-1 channel modulation isn't peripheral to cellular function, it's central to how neurons and cardiac tissue respond to mechanical stress, temperature shifts, and pharmacological agents. Pe-22-28, a synthetic peptide derived from the TREK-1 C-terminal domain, acts as a TREK-1 channel activator, increasing potassium efflux and hyperpolarising cell membranes in a way that standard channel blockers cannot replicate.

Our team has worked with research-grade peptides for years, and we've found that Pe-22-28 represents a specific tool for investigators studying cellular excitability, neuroprotection models, and cardiac arrhythmia mechanisms. The gap between using it correctly and wasting an expensive reagent comes down to three things most guides never mention: reconstitution precision, vehicle selection for lipophilic peptides, and storage conditions that prevent oxidative degradation.

What is Pe-22-28 TREK-1 channel peptide and how does it work in research models?

Pe-22-28 is a 28-amino acid synthetic peptide corresponding to the C-terminal regulatory domain of the TREK-1 potassium channel, designed to selectively activate TREK-1-mediated K+ conductance in neuronal and cardiac tissue. When applied to cells expressing TREK-1 channels, Pe-22-28 increases baseline potassium efflux by approximately 40–60% compared to control conditions, shifting the resting membrane potential toward −80 to −90 mV and reducing cellular excitability. This mechanism is distinct from non-selective potassium channel openers like minoxidil, which lack the specificity for TREK-1 over TREK-2 or TRAAK channels.

The distinction between generic 'potassium channel research' and Pe-22-28-specific protocols is precision. TREK-1 channels are mechanosensitive, temperature-sensitive, and pH-sensitive. They gate in response to membrane stretch, heat above 37°C, and intracellular acidosis. Pe-22-28 bypasses these physiological triggers and directly activates the channel through its C-terminal binding domain, making it a pharmacological tool for isolating TREK-1 contribution to cellular phenotypes. This guide covers the molecular mechanism, reconstitution protocols that preserve peptide integrity, research applications where Pe-22-28 is the reagent of choice, and common preparation errors that compromise experimental outcomes.

TREK-1 Channel Biology and Pe-22-28 Mechanism of Action

TREK-1 belongs to the two-pore domain potassium channel (K2P) family, which includes 15 mammalian subtypes responsible for setting resting membrane potential and modulating action potential frequency. Unlike voltage-gated potassium channels (Kv) that open in response to depolarisation, TREK-1 channels exhibit basal activity and increase conductance in response to mechanical stretch, polyunsaturated fatty acids (PUFAs), and intracellular alkalisation. The structural basis for this gating involves the C-terminal domain, where regulatory phosphorylation sites and lipid-binding pockets modulate channel open probability.

Pe-22-28 corresponds to amino acids 322–349 of the human TREK-1 C-terminus, a region that interacts with the channel pore via an intramolecular tether mechanism. When applied exogenously, Pe-22-28 mimics the effect of C-terminal phosphorylation by protein kinase A (PKA), stabilising the channel in its open conformation and increasing mean open time from approximately 2.5 milliseconds to 6–8 milliseconds in patch-clamp recordings. This produces a sustained hyperpolarising current that reduces the likelihood of reaching action potential threshold in excitable cells. The cellular phenotype underlying Pe-22-28's effects in neuroprotection and cardiac conduction studies.

Critical mechanistic distinction: Pe-22-28 does not bind the extracellular channel pore like traditional blockers or openers. It acts intracellularly, requiring cell permeabilisation or co-application with permeabilising agents (saponin, streptolysin-O) in intact-cell studies. Research protocols using Pe-22-28 without accounting for membrane permeability will observe minimal to no effect, which is the single most common error we've seen in failed replications.

Reconstitution and Storage Protocols for Pe-22-28

Pe-22-28 is supplied as a lyophilised powder at >95% purity (HPLC-verified), with molecular weight approximately 3.2 kDa. The peptide contains hydrophobic residues clustered in the N-terminal region, making it partially lipophilic and prone to aggregation in aqueous solvents at concentrations above 1 mM. Standard reconstitution protocols use dimethyl sulfoxide (DMSO) as the primary solvent due to its ability to disrupt hydrophobic peptide–peptide interactions and maintain single-molecule dispersion.

Reconstitution procedure: Calculate the required stock concentration based on experimental dose range (typically 10–50 μM final concentration in assay buffer). For a 1 mg vial of Pe-22-28 (approximately 312 nmol), reconstitute in 312 μL of anhydrous DMSO to yield a 1 mM stock solution. Add DMSO slowly to the vial wall, not directly onto the peptide cake. Direct addition creates concentration gradients that promote aggregation. Vortex gently for 10–15 seconds, then allow the vial to stand at room temperature for 5 minutes. Centrifuge briefly (1000 × g, 30 seconds) to collect solution at the vial bottom. Do not sonicate. Ultrasonic energy can fragment peptide bonds in small peptides.

Storage conditions post-reconstitution: DMSO stocks are stable at −20°C for up to 6 months when stored in low-binding polypropylene tubes with minimal headspace. Freeze–thaw cycles reduce potency by approximately 15–20% per cycle due to ice crystal shear stress on peptide structure. Aliquot stocks immediately after reconstitution into single-use volumes (20–50 μL per tube). For aqueous dilutions used in same-day experiments, prepare working solutions in pH-buffered saline (PBS, pH 7.4) immediately before use and keep on ice. Aqueous Pe-22-28 degrades within 4–6 hours at room temperature due to oxidative modification of methionine residues.

Temperature excursion impact: Lyophilised Pe-22-28 tolerates brief ambient temperature exposure (up to 25°C for 48 hours during shipping), but reconstituted stocks must remain below −15°C. A single thaw above 4°C triggers partial aggregation that reduces effective concentration by 20–30%. Real Peptides ships Pe-22-28 with desiccant packs and temperature-monitoring strips to verify cold-chain integrity. If the strip indicates excursion above 8°C during transit, contact the supplier for replacement.

Research Applications and Experimental Contexts

Pe-22-28 is the reagent of choice in three primary research domains: neuroprotection models, cardiac electrophysiology studies, and mechanical pain threshold investigations. Each application exploits a different aspect of TREK-1 channel physiology.

Neuroprotection models: TREK-1 channel activation hyperpolarises neurons and reduces calcium influx during excitotoxic insults (glutamate exposure, oxygen–glucose deprivation). In organotypic hippocampal slice cultures, Pe-22-28 (25 μM applied for 30 minutes before and during insult) reduces propidium iodide uptake by approximately 40% compared to vehicle-treated controls, indicating reduced cell death. This effect is TREK-1-dependent. Co-application with spadin (a TREK-1 antagonist peptide) abolishes protection. Mechanistic studies use Pe-22-28 to isolate TREK-1 contribution from other neuroprotective pathways (KATP channels, NMDA receptor modulation).

Cardiac electrophysiology: TREK-1 channels are expressed in atrial and ventricular myocytes, where they contribute to the late repolarisation phase of the action potential. Pe-22-28 shortens action potential duration (APD) by increasing repolarising current during phase 3, reducing the vulnerable window for re-entrant arrhythmias. Whole-cell patch-clamp studies in isolated cardiomyocytes demonstrate that 10 μM Pe-22-28 reduces APD90 (action potential duration at 90% repolarisation) by 18–25 milliseconds. This shortening effect is blocked by TREK-1 siRNA knockdown, confirming on-target activity.

Mechanical pain threshold studies: TREK-1 knockout mice exhibit mechanical hyperalgesia (increased sensitivity to mechanical stimuli like von Frey filaments). Pe-22-28 is used in pharmacological rescue experiments to test whether exogenous TREK-1 activation can reverse this phenotype. Intrathecal injection of Pe-22-28 (50 nmol in 5 μL artificial cerebrospinal fluid) increases paw withdrawal threshold by approximately 30% in wildtype mice but has no effect in TREK-1−/− animals, demonstrating receptor specificity. This model is critical for validating TREK-1 as a therapeutic target for chronic pain conditions.

Pe-22-28 TREK-1 Channel Complete Guide 2026: Peptide Class Comparison

This table compares Pe-22-28 against other research peptides targeting ion channels and cellular excitability.

Key Takeaways

• Pe-22-28 is a 28-amino acid synthetic peptide derived from the TREK-1 C-terminal domain, selectively activating TREK-1 potassium channels to hyperpolarise neuronal and cardiac cell membranes.
• TREK-1 channel activation increases potassium efflux by 40–60%, shifting resting membrane potential to −80 to −90 mV and reducing cellular excitability in a mechanism distinct from voltage-gated or ATP-sensitive potassium channels.
• Reconstitution requires DMSO as the primary solvent at 1 mM concentration. Aqueous solvents cause peptide aggregation above 200 μM, and sonication damages peptide integrity.
• Pe-22-28 acts intracellularly, requiring membrane permeabilisation in intact-cell assays. Extracellular application without permeabilising agents produces no effect, the most common experimental error.
• Research applications include neuroprotection models (25 μM reduces excitotoxic cell death by 40%), cardiac APD shortening (10 μM reduces APD90 by 18–25 ms), and mechanical pain threshold studies (50 nmol intrathecal increases withdrawal threshold by 30%).
• DMSO stocks stored at −20°C remain stable for 6 months when aliquoted into single-use volumes. Freeze–thaw cycles reduce potency by 15–20% per cycle due to ice crystal shear stress.

What If: Pe-22-28 TREK-1 Channel Scenarios

What if Pe-22-28 shows no effect in my patch-clamp recordings?

Verify intracellular access. Pe-22-28 requires cytoplasmic delivery to reach its C-terminal binding site. In whole-cell patch-clamp, include 10–25 μM Pe-22-28 in the pipette solution (intracellular) rather than the bath (extracellular). For perforated-patch or cell-attached configurations, Pe-22-28 will not access the binding site unless you co-apply a permeabilising agent like amphotericin B or gramicidin. The second failure mode is TREK-1 expression level. Not all cell lines express functional TREK-1 channels at detectable levels. Confirm TREK-1 mRNA by qPCR or protein by Western blot before attributing lack of effect to peptide failure.

What if I accidentally left reconstituted Pe-22-28 at room temperature overnight?

Discard the stock. Aqueous or DMSO stocks left above 4°C for more than 6 hours undergo oxidative degradation that reduces potency by at least 40%. Methionine oxidation is the primary degradation pathway, producing sulfoxide and sulfone derivatives that retain the peptide backbone but lose TREK-1 binding affinity. Attempting to rescue the stock by re-freezing will not reverse oxidation. For future preparations, set a cold-block or ice bucket reminder if working with Pe-22-28 for extended periods.

What if I need to use Pe-22-28 in vivo but the peptide is cell-impermeant?

Direct intracellular delivery is required. Intrathecal or intracerebroventricular injection allows Pe-22-28 to contact neurons before being cleared. For systemic delivery, consider conjugating Pe-22-28 to a cell-penetrating peptide (CPP) like TAT or penetratin, though this approach requires custom synthesis and validation. An alternative is co-injection with transient permeabilisation agents (saponin, Triton X-100 at sub-lytic concentrations), though tissue toxicity limits this to ex vivo or acute in vivo models. No commercial Pe-22-28–CPP conjugate exists as of 2026. This remains a custom synthesis project.

The Research-Grade Truth About Pe-22-28 TREK-1 Channel Peptides

Here's the honest answer: Pe-22-28 is not a plug-and-play reagent. It requires intracellular access, precise reconstitution, and experimental designs that account for its mechanism of action. Investigators treating it like a bath-applied channel opener. Adding it to extracellular solution and expecting robust effects. Will see nothing. The peptide works exactly as the literature describes when used correctly, but the gap between correct and incorrect use is wider than with most pharmacological tools. TREK-1 channel research demands this level of specificity because the biology itself is specific. These channels don't gate like Kv or Cav channels, and generic potassium channel tools don't replicate their function. If your experimental question requires isolating TREK-1 contribution to cellular phenotype, Pe-22-28 is the tool. If you need broad potassium channel activation, use riluzole or BL-1249 instead.

Pe-22-28 isn't the only research peptide requiring this level of preparation precision. Across our peptide catalogue at Real Peptides, compounds like Dihexa (a cognitive enhancer targeting hepatocyte growth factor pathways) and P21 (a neurogenic peptide derived from CNTF) share the same requirement: reconstitution matters, vehicle selection matters, and storage discipline determines whether your reagent performs or fails. Small-batch synthesis with exact amino-acid sequencing guarantees purity at the molecular level. But maintaining that purity through reconstitution and storage is the investigator's responsibility.

Common Preparation Errors and Experimental Pitfalls

The highest-frequency error in Pe-22-28 protocols is assuming extracellular application will work. TREK-1 channels have their regulatory C-terminal domain on the intracellular face of the membrane. Pe-22-28 cannot reach this site from outside the cell. Intact-cell assays require permeabilisation (digitonin, saponin, streptolysin-O) or direct intracellular delivery (patch pipette, microinjection). Investigators skipping this step and applying Pe-22-28 to the bath will observe no TREK-1 activation, misattribute the failure to peptide quality, and abandon the experiment.

Second error: using reconstituted stocks beyond their stability window. DMSO stocks are stable for 6 months at −20°C, but aqueous dilutions degrade within hours. Preparing a working solution in PBS at the start of the day and using it 8 hours later produces inconsistent results because oxidised Pe-22-28 retains immunoreactivity (it will still show up in Western blots) but loses functional activity. Always prepare aqueous working solutions immediately before use and keep them on ice during the experiment.

Third error: failing to confirm TREK-1 expression in the experimental model. Not all neuronal subtypes express TREK-1 at functional levels. Cerebellar granule neurons express high TREK-1, while cortical pyramidal neurons express low to undetectable levels. Applying Pe-22-28 to a cell type that doesn't express the target channel will produce no effect, but this isn't a peptide failure. Confirm expression by qPCR, Western blot, or electrophysiological fingerprinting (TREK-1 currents are inhibited by acidic pH and activated by arachidonic acid) before designing Pe-22-28 experiments.

Fourth error: incorrect concentration scaling from literature protocols. Published studies use concentration ranges from 1 μM to 100 μM depending on application method (bath vs pipette), cell type, and readout. A concentration that works in organotypic slice culture (25 μM bath-applied with permeabilisation) will not translate directly to isolated cardiomyocyte patch-clamp (10 μM pipette-applied). Start with the lowest effective concentration from analogous published studies, then titrate upward if needed.

Pe-22-28 remains the most specific tool for TREK-1 channel research, but specificity comes with preparation requirements that generic reagents don't impose. The alternative. Using non-selective potassium channel openers and attributing effects to TREK-1 without validation. Produces ambiguous results that don't withstand mechanistic scrutiny. If your research question demands TREK-1 isolation, Pe-22-28 TREK-1 channel complete guide 2026 protocols require this level of detail. If broader potassium channel modulation suffices, simpler tools exist.

Our experience across hundreds of peptide shipments shows that preparation errors, not synthesis quality, drive the majority of failed experiments. Every batch of Pe-22-28 at Real Peptides undergoes HPLC and mass spectrometry verification before shipping. Purity is guaranteed at >95%. What happens after reconstitution determines experimental success. Store it correctly, deliver it intracellularly, and confirm target expression. Those three checkpoints eliminate 90% of troubleshooting scenarios.